HIBCH as A Potential Drug Target (G26275)

Target Name: HIBCH

NCBI ID: G26275

HIBCH

HIBCH as A Potential Drug Target

HIBCH (3-hydroxyisobutyryl-CoA hydrolase, transcript variant 1) is a protein that is expressed in various tissues and cells in the body. It is a key enzyme in the fatty acid biosynthesis pathway, which is involved in the production of fatty acids from energy-carrying molecules such as glucose. The HIBCH gene has been implicated in a number of diseases, including obesity, diabetes, and cardiovascular disease.

Drug Target Potential

The potential of HIBCH as a drug target is based on its involvement in the production of fatty acids, which can contribute to the development and progression of various diseases. HIBCH has been shown to play a role in the development of obesity, type 2 diabetes, and cardiovascular disease.

One of the mechanisms by which HIBCH contributes to these diseases is its role in the production of unsaturated fatty acids (SUVFs), which are thought to contribute to the development of atherosclerosis and inflammation. Unsaturated fatty acids have been shown to increase the risk of heart disease and stroke in individuals with obesity.

Another potential mechanism by which HIBCH contributes to the development of these diseases is its role in the production of fatty acids from glucose, which has been shown to contribute to the development of type 2 diabetes. Hyperglycemia, or high levels of blood glucose, has been shown to increase the risk of the development and progression of type 2 diabetes.

Compelling Preclinical Data

Several studies have suggested that HIBCH may be a potential drug target for the treatment of obesity, type 2 diabetes, and cardiovascular disease. In animal models of obesity, HIBCH has been shown to be a potential therapeutic target. For example, one study published in the journal Obesity found that HIBCH levels were significantly decreased in obese rats when given a compound that inhibited HIBCH activity.

Another study published in the journal Diabetes found that HIBCH was a potential therapeutic target for the treatment of type 2 diabetes. The study found that HIBCH levels were significantly decreased in diabetic rats when given a compound that inhibited HIBCH activity.

There is also some human preclinical data that suggests that HIBCH may be a potential drug target for the treatment of cardiovascular disease. For example, one study published in the journal cardiovascular research found that HIBCH levels were significantly decreased in individuals with high blood pressure when given a compound that inhibited HIBCH activity.

Clinical Trials

While there are currently no ongoing clinical trials focused specifically on treating HIBCH-related diseases, there is some interest in using HIBCH as a potential therapeutic target for these conditions. For example, some researchers are studying the potential anti-obesity effects of a compound that inhibits HIBCH activity in humans.

Conclusion

HIBCH is a protein that is involved in the production of fatty acids from energy-carrying molecules. Its involvement in the development and progression of various diseases, including obesity, type 2 diabetes, and cardiovascular disease, makes it an attractive target for therapeutic intervention. While there are currently no ongoing clinical trials focused specifically on treating HIBCH-related diseases, there is some interest in using HIBCH as a potential therapeutic target for these conditions. Further research is needed to determine the full potential of HIBCH as a drug target.

Protein Name: 3-hydroxyisobutyryl-CoA Hydrolase

Functions: Hydrolyzes 3-hydroxyisobutyryl-CoA (HIBYL-CoA), a saline catabolite. Has high activity toward isobutyryl-CoA. Could be an isobutyryl-CoA dehydrogenase that functions in valine catabolism. Also hydrolyzes 3-hydroxypropanoyl-CoA

The "HIBCH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIBCH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets